Learn how immune health differs between smoldering and multiple myeloma, with insights showing earlier-stage disease may have stronger immune function and better overall resilience.
Explore how using CAR-T cell therapy earlier in treatment may improve outcomes, with new insights suggesting earlier intervention could lead to better response and long-term results.
Francesco Corrado explained the research question from the oral abstract he presented at ASH 2025, where he and a group of researchers at the Dana-Farber Cancer Institute investigated the efficacy of CAR-T cells when administered at an earlier stage of the disease.
Nayda Bidikian discusses the oral abstract she presented at ASH 2025, where she talked about how because immune dysregulation worsens in multiple myeloma as the disease progresses, they profiled patients’s immune system with peripheral blood samples and compared their status posttreatment to baseline.
Romanos Sklavenitis-Pistofidis, MD, discusses that now that patients with smoldering myeloma have a treatment option as standard of care, it changes the landscape and how healthcare professionals consider genomic and immune biomarkers in this patient population.
Rodger Tiedemann, MD, PhD, discusses several translocations that can occur in myleoma, noting that B cells from the germinal center are sometimes the carrier of clonal mutations.
Rodger Tiedemann, MD, PhD, investigated whether the plasma cells pre-treatment give rise to the plasma cells after tretament. He found that in many cases, myeloma plasma cells at relapse can arise from the pre-treatment myeloma B cell compartment, and not necessarily from the myeloma plasma cells.
Romanos Sklavenitis-Pistofidis, MD, shares the advances in the field of genomic biomarkers throughout the year, citing whole genome sequencing–based risk stratification tools that were published.
©2026 Oncology Matrix. All Rights Reserved.
